Nxera Pharma Partners With Synmosa to License Insomnia Drug QUVIVIQ Across Eight Asia-Pacific Markets
Nxera Pharma Co., Ltd. (TSE:4565) has entered into an exclusive licensing, commercialization, and supply agreement with Synmosa for its insomnia treatment QUVIVIQ (daridorexant). The deal covers eight Asia-Pacific markets, including Singapore, Thailand, Indonesia, Malaysia, the Philippines, Vietnam, Australia, and New Zealand. Shares of Nxera Pharma traded down 3.03% to 1183 JPY following the announcement.
Under the terms of the agreement, Synmosa will oversee local regulatory submissions and sales activities across the specified territories. In exchange, Nxera Pharma will receive upfront payments, progress-based regulatory milestone funding, and ongoing sales royalties. Additionally, Nxera Pharma will generate revenue by supplying the drug product directly to Synmosa.
This deal broadens Nxera Pharma's presence in the Asia-Pacific region beyond its established operations in Japan and Taiwan-linked territories. By handing regulatory and marketing responsibilities to a local partner, the company aims to expand commercial reach while controlling operational costs. Investors will be monitoring national regulatory approvals and subsequent prescription growth as key drivers for future royalty and supply streams.
Key points
- Nxera Pharma Co., Ltd. (TSE:4565) granted Synmosa an exclusive license for QUVIVIQ in eight Asia-Pacific countries, including Australia and Vietnam.
- The deal structure includes upfront cash, regulatory milestone payments, ongoing royalties, and drug product supply revenue for Nxera Pharma.
- Synmosa will handle regulatory filings and commercialization efforts, helping lower Nxera Pharma's regional operational expenses.
- The agreement extends Nxera Pharma's commercial strategy in the Asia-Pacific region beyond Japan and Taiwan.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What is the agreement between Nxera Pharma and Synmosa?
Nxera Pharma granted Synmosa an exclusive license to commercialize and distribute QUVIVIQ across eight Asia-Pacific markets, with Nxera supplying the drug and earning royalties and milestone payments.
Which markets are included in the QUVIVIQ licensing agreement?
The agreement covers Singapore, Thailand, Indonesia, Malaysia, the Philippines, Vietnam, Australia, and New Zealand.
How does Nxera Pharma benefit financially from this deal?
Nxera Pharma receives upfront cash, regulatory milestone payments, royalties on Synmosa's sales, and revenue from supplying the finished drug product.